Log in

Akcea Therapeutics Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $18.14
50-Day Range
MA: $14.80
52-Week Range
Now: $18.14
Volume657,097 shs
Average Volume354,366 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More
Akcea Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.11 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:AKCA



Sales & Book Value

Annual Sales$488.54 million
Cash Flow$0.51 per share
Book Value$5.78 per share


Net Income$40.77 million


Market Cap$1.84 billion
Next Earnings Date11/3/2020 (Estimated)
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

How has Akcea Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AKCA shares have increased by 35.0% and is now trading at $18.14.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Akcea Therapeutics

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Akcea Therapeutics

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) announced its earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.14. The firm earned $22.38 million during the quarter, compared to analyst estimates of $30.93 million. Akcea Therapeutics had a negative net margin of 12.34% and a negative return on equity of 8.94%. The firm's revenue was down 15.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.40) EPS.
View Akcea Therapeutics' earnings history

What price target have analysts set for AKCA?

4 brokers have issued twelve-month target prices for Akcea Therapeutics' shares. Their forecasts range from $18.15 to $41.00. On average, they anticipate Akcea Therapeutics' share price to reach $29.58 in the next twelve months. This suggests a possible upside of 63.0% from the stock's current price.
View analysts' price targets for Akcea Therapeutics

Are investors shorting Akcea Therapeutics?

Akcea Therapeutics saw a drop in short interest in September. As of September 15th, there was short interest totaling 1,170,000 shares, a drop of 60.3% from the August 31st total of 2,950,000 shares. Based on an average daily trading volume, of 511,400 shares, the days-to-cover ratio is presently 2.3 days. Approximately 7.0% of the company's stock are short sold.
View Akcea Therapeutics' Short Interest

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Advanced Micro Devices (AMD), Apollo Global Management (APO) and Exelixis (EXEL).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the following people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager.

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (10.44%), Vanguard Group Inc. (1.44%), Bellevue Group AG (1.44%), Point72 Asset Management L.P. (0.25%), Charles Schwab Investment Management Inc. (0.17%) and Alps Advisors Inc. (0.14%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce.
View institutional ownership trends for Akcea Therapeutics

Which major investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, FMR LLC, Marshall Wace LLP, Skandinaviska Enskilda Banken AB publ, Alps Advisors Inc., Amia Capital LLP, Nuveen Asset Management LLC, and Tudor Investment Corp Et Al. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Joshua F Patterson, and Kyle Jenne.
View insider buying and selling activity for Akcea Therapeutics

Which major investors are buying Akcea Therapeutics stock?

AKCA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Vanguard Group Inc., PDT Partners LLC, SG Americas Securities LLC, Prudential Financial Inc., Hancock Whitney Corp, Charles Schwab Investment Management Inc., and California Public Employees Retirement System.
View insider buying and selling activity for Akcea Therapeutics

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $18.14.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.84 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is www.akceatx.com.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.